China Resources Boya Biopharmaceutical

China Resources Boya Biopharmaceutical Group is a leading Chinese biopharmaceutical company specializing in the research, development, and production of plasma-derived therapeutics. As a core subsidiary of the state-owned China Resources Group, the company operates a vertically integrated model encompassing plasma collection, fractionation, and the manufacturing of critical treatments such as human albumin, immunoglobulins, and coagulation factors. The company holds a significant market position in China's highly regulated blood products industry, maintaining numerous plasma collection centers across several provinces. In addition to its core plasma business, the group has diversified into diabetes treatments and chemical pharmaceuticals through strategic acquisitions and subsidiary operations. Headquartered in Jiangxi Province, the company is listed on the Shenzhen Stock Exchange and continues to expand its pipeline with advanced blood-derived proteins and recombinant technologies.